NCT04275050View on ClinicalTrials.gov

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3303 Tablets

PHASE1UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 30, 2020

Primary Completion Date

April 30, 2021

Study Completion Date

April 30, 2022

Conditions
Advanced Malignant Solid Tumor
Interventions
DRUG

TQB3303

TQB3303 tablet is a small molecule oral drug inhibiting cyclin-dependent kinases 4 and 6 (CDK4 / 6).

Trial Locations (1)

Unknown

Chinese Academy of Medical Sciencesand Peking Union Medical College, Beijing

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY